EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Feasibility and acceptability of GeneXpert MTB/XDR implementation among healthcare workers in three low-middle income African countries

Sara Keller, Kogieleum Naidoo iD, Medhane Zekarias, Sussan Israel-Isah, Mohammed Shaka, Gcinile Gule, Anushka Naidoo, Miriam Bathnna, Judith Nomthandazo Dlamini-Miti, Kalkidan Yae, Evaezi Okpokoro, Alash'le Abimiku und 3 weitere

PLOS One · 24.06.2025 · 20 (6) · e0326342

DOI: 10.1371/journal.pone.0326342 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift PLOS One, online erschienen am 24.06.2025. Verfasst von Sara Keller und 14 weiteren Autor:innen. Beteiligte Einrichtung: KNCV Tuberculosis Foundation, Den Haag, The Netherlands. Hauptthemen laut MEDLINE: Health Personnel, Tuberculosis, Multidrug-Resistant, Mycobacterium tuberculosis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European and Developing Countries Clinical Trials Partnership.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Xpert MTB/XDR (Xpert-XDR) testing can significantly shorten time to initiating appropriate drug-resistant tuberculosis (DR-TB) treatment, but its introduction may impact laboratory workflow, especially in laboratories not currently performing drug susceptibility testing. This study evaluated the feasibility and acceptability of implementing the Xpert-XDR for rapid triage and selection of all-oral regimens for DR-TB.

Method

This was a multi-country, multi-site qualitative study conducted between July and November 2023, as part of the larger TriAD (Triage test for All oral DR TB drugs) study implemented in South Africa, Ethiopia, and Nigeria. We conducted semi-structured in-depth interviews with clinicians, nurses and laboratory staff at each study site until thematic saturation was achieved. Additionally, we interviewed policy makers (n = 9) and people with TB (PWTB) (n = 11), to provide additional insight on the implementation of this new diagnostic assay.

Results

Healthcare workers (n = 61) found the new workflow feasible and acceptable. It was the increased speed in which PWTB would receive a correct diagnosis and appropriate treatment that provided the biggest benefit to moving to Xpert-XDR for healthcare workers and PWTB. Laboratory staff mentioned that Xpert-XDR had expedited and simplified the laboratory workflows. Role-appropriate and ongoing training is a key factor in effective implementation as described by policy makers and healthcare workers alike. Barriers impacting the ability to perform Xpert-XDR included unstable power supply, internet, and temperature control. Additionally, the Xpert MTB/Rif Ultra test has higher sensitivity for the detection of TB than the Xpert-XDR test, leading to discordant test results.

Conclusion

This study showed that implementation of Xpert-XDR in health facilities is both feasible and acceptable by all types of healthcare workers. Some barriers with Xpert-XDR are not exclusive to this particular diagnostic tool but are important to address when policy makers are deciding which tools to implement.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Health PersonnelTuberculosis, Multidrug-ResistantMycobacterium tuberculosisHumansEthiopiaFeasibility StudiesSouth AfricaNigeriaFemaleMaleAdult

Autor:innen und Institutionen

  • KNCV Tuberculosis Foundation, Den Haag, The Netherlands.
  • Centre for the Aids Programme of Research in South Africa, Durban, KwaZulu-Natal, South Africa.
  • SAMRC-CAPRISA HIV-TB Pathogenesis and Treatment Research Unit, Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, KwaZulu-Natal, South Africa.
  • KNCV Tuberculosis Foundation, Ethiopia Office, Addis Ababa, Ethiopia.
  • International Research Centre of Excellence- Institute of Human Virology, Abuja, Nigeria.
  • University of the Witwatersrand, Johannesburg, South Africa.

ORCID-Profile: Kogieleum Naidoo, Edine W Tiemersma

Förderung

  • European and Developing Countries Clinical Trials Partnership

Zitieren

APA

Keller, S., Naidoo, K., Zekarias, M., Israel-Isah, S., Shaka, M., Gule, G., Naidoo, A., Bathnna, M., Dlamini-Miti, J. N., Yae, K., Okpokoro, E., Abimiku, A., Bedru, A., Tiemersma, E. W., & TRiAD Study Consortium (2025). Feasibility and acceptability of GeneXpert MTB/XDR implementation among healthcare workers in three low-middle income African countries. PLOS One, 20(6), e0326342. https://doi.org/10.1371/journal.pone.0326342

Vancouver

Keller S, Naidoo K, Zekarias M, Israel-Isah S, Shaka M, Gule G, et al. Feasibility and acceptability of GeneXpert MTB/XDR implementation among healthcare workers in three low-middle income African countries. PLOS One. 2025;20(6):e0326342. doi:10.1371/journal.pone.0326342

BibTeX
@article{Keller2025,
  author = {Keller, Sara and Naidoo, Kogieleum and Zekarias, Medhane and Israel-Isah, Sussan and Shaka, Mohammed and Gule, Gcinile and Naidoo, Anushka and Bathnna, Miriam and Dlamini-Miti, Judith Nomthandazo and Yae, Kalkidan and Okpokoro, Evaezi and Abimiku, Alash'le and Bedru, Ahmed and Tiemersma, Edine W and TRiAD Study Consortium, TRiAD Study Consortium},
  title = {Feasibility and acceptability of GeneXpert MTB/XDR implementation among healthcare workers in three low-middle income African countries},
  journal = {PLOS One},
  year = {2025},
  volume = {20},
  number = {6},
  pages = {e0326342},
  doi = {10.1371/journal.pone.0326342}
}
Kostenlos starten →